Migraine drug may boost CAR-T therapy in tough lymphoma
NCT ID NCT07613788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding the migraine drug rimegepant to a standard CAR-T cell therapy and another immunotherapy (glofitamab) can improve outcomes for people with high-risk relapsed or refractory large B-cell lymphoma. About 100 adults will be randomly assigned to receive the combination with or without rimegepant. The main goal is to see how many patients achieve a complete response (no detectable cancer) at 6 months after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rimegepant, glofitamab, obinutuzumab, and CD19 CAR-T cells
- What this could lead to
- If successful, this combination could improve the chance of complete remission for patients with hard-to-treat lymphoma.
- What could go wrong
- This is an early Phase 2 trial with only 100 participants. The added benefit of rimegepant is unproven, and side effects from the combination may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China, 200020, China